Surmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum
October 26 2017 - 4:05PM
Business Wire
Webcast is Live on Thursday, November 9, at 9
a.m. (ET)
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical
device and in vitro diagnostic technologies to the healthcare
industry, today announced that Gary Maharaj, president and chief
executive officer, and Andy LaFrence, vice president of finance and
information systems and chief financial officer, will make a
presentation to the investment community at the Canaccord Genuity
Medical Technologies and Diagnostics Forum in New York City on
Thursday, November 9, 2017, at 9 a.m. ET
(8 a.m. CT).
A live audio webcast of the presentation will be available by
going to the investor relations portion of the Company’s website at
www.surmodics.com and clicking on the webcast icon. The webcast
will be archived on the Company’s website for 90 days following the
live presentation.
About Surmodics, Inc.
Surmodics is the global leader in surface modification
technologies for intravascular medical devices and a leading
provider of chemical components for in vitro diagnostic (IVD) tests
and microarrays. Following two recent acquisitions of Creagh
Medical and NorMedix, the Company is executing a key growth
strategy for its medical device business by expanding to offer
total intravascular product solutions to its medical device
customers. The combination of proprietary surface technologies,
along with enhanced device design, development and manufacturing
capabilities, enables Surmodics to significantly increase the value
it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements.
With this focus on offering total solutions, Surmodics’ mission
remains to improve the detection and treatment of disease.
Surmodics is headquartered in Eden Prairie, Minnesota. For more
information about the company, visit www.surmodics.com. The content
of Surmodics’ website is not part of this press release or part of
any filings that the company makes with the SEC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171026005293/en/
Surmodics, Inc.Andy LaFrence, 952-500-7000ir@surmodics.com
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From Apr 2024 to May 2024
SurModics (NASDAQ:SRDX)
Historical Stock Chart
From May 2023 to May 2024